dc.contributor.author | Ryan, Pablo | |
dc.contributor.author | Valencia, Jorge | |
dc.contributor.author | Cuevas, Guillermo | |
dc.contributor.author | Torres-Macho, Juan | |
dc.contributor.author | Troya, Jesús | |
dc.contributor.author | Pueyo, Ángel | |
dc.contributor.author | Muñoz-Gómez, María José | |
dc.contributor.author | Muñoz-Rivas, Nuria | |
dc.contributor.author | Vázquez-Morón, Sonia | |
dc.contributor.author | Martinez, Isidoro | |
dc.contributor.author | Lazarus, Jeffrey V | |
dc.contributor.author | Resino, Salvador | |
dc.date.accessioned | 2024-05-22T08:42:58Z | |
dc.date.available | 2024-05-22T08:42:58Z | |
dc.date.issued | 2021-10 | |
dc.identifier.citation | Int J Drug Policy. 2021 Oct:96:103424. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/19518 | |
dc.description.abstract | Background: The burden of hepatitis C virus (HCV) infection among marginalized people in Spain is high, despite the fact that HCV prevalence has decreased in recent years. We aimed to assess the effectiveness of a simplified point-of-care (PoC) model for screening for active HCV infection via a mobile unit and subsequent linkage to care with the assistance of navigators. Methods: We carried out a prospective study on 2001 participants from Madrid, Spain. A nurse and a navigator/educator screened for hepatitis C in a mobile unit, using the OraQuick HCV Rapid Antibody Test and Xpert HCV VL Fingerstick assay. Participants with active HCV were referred to the hospital the same day with a navigator for evaluation and treatment of HCV. Results: Overall, 1621 (81%) participants had not been exposed to HCV, 380 (18.9%) were positive for HCV antibodies, and 136 (6.8%) had active hepatitis C. Among the latter, 134 (98.5%) received the HCV screening results, 133 (97.8%) had an appointment at the hospital, 126 (92.8%) were seen by a physician once they were at the hospital, and 105 (77.2%) started HCV treatment. Being over 50 years old and a person who uses drugs, particularly people who inject drugs (PWID), was directly associated with active hepatitis C (p<0.05). PWID were the only patients with HCV reinfection (4.3% in people without recent injecting drug use and 5.9% in people with recent injecting drug use). Among PWID, no income and daily alcohol intake were also directly associated with active hepatitis C. People with recent injecting drug use showed the lowest rates of attendance at the hospital (91.8%) and starting HCV treatment (70.4%). Conclusion: HCV screening using a two-step PoC-based strategy and its linkage to care was extremely efficient for identifying and treating marginalized people with active hepatitis C, thanks to the use of a mobile unit with personnel and technical equipment, an interdisciplinary team, and collaboration between institutions. | es_ES |
dc.description.sponsorship | This work was funded by a research grant from Gilead Science (IN-ES-987-5391 and GLD20_0144) and Instituto de Salud Carlos III (ISCII; grant numbers PI20CIII/00004 and RD16CIII/0002/0002 to SR). It also received funding from AbbVie, Asociación Española para Estudio del Higado (AEEH), and Madrid Positivo Association. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | SMUR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Hepatitis C | es_ES |
dc.subject | Screening mobile unit | es_ES |
dc.subject | People who use drugs | es_ES |
dc.subject | Point-of-care | es_ES |
dc.subject | Linkage-to-care | es_ES |
dc.subject | HCV testing | es_ES |
dc.subject | HCV treatment | es_ES |
dc.subject | Spain | es_ES |
dc.subject.mesh | Hepatitis C | es_ES |
dc.subject.mesh | Substance Abuse, Intravenous | es_ES |
dc.subject.mesh | Antiviral Agents | es_ES |
dc.subject.mesh | Hepacivirus | es_ES |
dc.subject.mesh | Hepatitis C Antibodies | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Middle Aged | es_ES |
dc.subject.mesh | Prospective Studies | es_ES |
dc.subject.mesh | Spain | es_ES |
dc.title | Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 34429222 | es_ES |
dc.format.volume | 96 | es_ES |
dc.format.page | 103424 | es_ES |
dc.identifier.doi | 10.1016/j.drugpo.2021.103424 | es_ES |
dc.contributor.funder | Gilead Sciences (Spain) | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | AbbVie | es_ES |
dc.contributor.funder | Asociación Española para Estudio del Higado (AEEH) | es_ES |
dc.contributor.funder | Madrid Positivo Association | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1873-4758 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.drugpo.2021.103424 | es_ES |
dc.identifier.journal | The International journal on drug policy | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/Subprograma Estatal de Generación de Conocimiento/PI20-ISCIII Modalidad Proyectos de Investigacion en Salud Intramurales. (2020)/PI20CIII/00004 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/RD16CIII/0002/0002 | es_ES |